121 related articles for article (PubMed ID: 6817364)
1. Dose-response relationships of perphenazine in the treatment of acute psychoses.
Hansen LB; Larsen NE; Gulmann N
Psychopharmacology (Berl); 1982; 78(2):112-5. PubMed ID: 6817364
[TBL] [Abstract][Full Text] [Related]
2. Plasma levels of perphenazine (Trilafon) related to development of extrapyramidal side effects.
Hansen LB; Larsen NE; Vestergård P
Psychopharmacology (Berl); 1981; 74(4):306-9. PubMed ID: 6794071
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic advantages of monitoring plasma concentrations of perphenazine in clinical practice.
Hansen LB; Larsen NE
Psychopharmacology (Berl); 1985; 87(1):16-9. PubMed ID: 3933033
[TBL] [Abstract][Full Text] [Related]
4. The relationship between blood perphenazine levels, early resolution of psychotic symptoms, and side effects.
Mazure CM; Nelson JC; Jatlow PI; Kincare P; Bowers MB
J Clin Psychiatry; 1990 Aug; 51(8):330-4. PubMed ID: 2199431
[TBL] [Abstract][Full Text] [Related]
5. Extrapyramidal symptoms following administration of oral perphenazine 4 or 8 mg: an 11-year retrospective analysis.
Henao JP; Peperzak KA; Lichvar AB; Orebaugh SL; Skledar SJ; Pippi MA; Williams BA
Eur J Anaesthesiol; 2014 Apr; 31(4):231-5. PubMed ID: 24503705
[TBL] [Abstract][Full Text] [Related]
6. Loxapine versus perphenazine in psychotic patients. A double-blind, randomized, multicentre trial.
Fruensgaard K; Wollenberg J; Hansen KM; Fensbo C; Sihm F
Curr Med Res Opin; 1978; 5(8):601-7. PubMed ID: 361345
[TBL] [Abstract][Full Text] [Related]
7. Perphenazine decanoate vs. perphenazine enanthate: efficacy and side effects in a 6 week double-blind, comparative study of 50 drug monitored psychotic patients.
Knudsen P; Hansen LB; Auken G; Waehrens J; Højholdt K; Larsen NE
Acta Psychiatr Scand Suppl; 1985; 322():15-28. PubMed ID: 3907278
[TBL] [Abstract][Full Text] [Related]
8. Extrapyramidal symptoms and their relationship to clinical efficacy under perphenazine treatment. A controlled prospective handwriting-test study in 22 acutely ill schizophrenic patients.
Gerken A; Wetzel H; Benkert O
Pharmacopsychiatry; 1991 Jul; 24(4):132-7. PubMed ID: 1754609
[TBL] [Abstract][Full Text] [Related]
9. [Perphenazine enantate in long-term therapy of psychoses].
Gunby B
Nord Psykiatr Tidsskr; 1968; 22(4):358-60. PubMed ID: 5710606
[No Abstract] [Full Text] [Related]
10. The relationship between perphenazine plasma levels and clinical response in acute schizophrenia.
Omérov M; Wistedt B; Bolvig-Hansen L; Larsen NE
Prog Neuropsychopharmacol Biol Psychiatry; 1989; 13(1-2):159-66. PubMed ID: 2664884
[TBL] [Abstract][Full Text] [Related]
11. Plasma concentrations of perphenazine and its sulphoxide metabolite during continuous oral treatment.
Hansen LB; Larsen NE
Psychopharmacology (Berl); 1977 Jul; 53(2):127-30. PubMed ID: 408838
[TBL] [Abstract][Full Text] [Related]
12. Zuclopenthixol and perphenazine in patients with acute psychotic states. A double-blind multicentre study.
Remvig J; Larsen H; Rask P; Skausig OB; Skov S; Strömgren LS
Pharmacopsychiatry; 1987 Jul; 20(4):147-54. PubMed ID: 3615572
[TBL] [Abstract][Full Text] [Related]
13. [Results of treatment of schizophrenic and schizoaffective patients with sulpiride (Eglonyl Alkaloid) in comparison with perphenazine (Perfenazin Spofa)].
Svestka J; Rysánek R; Náhunek K; Cesková E
Cesk Psychiatr; 1990 Jun; 86(3):145-56. PubMed ID: 2225184
[TBL] [Abstract][Full Text] [Related]
14. Long-term depot neuroleptic treatment with perphenazine decanoate. I. Efficacy and side effects in a 12 month study of 42 drug monitored psychotic patients.
Knudsen P; Hansen LB; Højholdt K; Larsen NE
Acta Psychiatr Scand Suppl; 1985; 322():29-40. PubMed ID: 3907279
[TBL] [Abstract][Full Text] [Related]
15. Switching patients from olanzapine or risperidone to a combination treatment using perphenazine plus buspirone: evaluation of antipsychotic efficacy and side-effects, including extrapyramidal effects and weight loss.
Andersen TH; Bech P; Larsen NE
Nord J Psychiatry; 2005; 59(3):205-8. PubMed ID: 16195121
[TBL] [Abstract][Full Text] [Related]
16. Neuroleptic malignant syndrome during perphenazine treatment.
Nielsen D; Aunsholt NA; Andersen PT
Pharmacol Toxicol; 1987 Mar; 60(3):221-2. PubMed ID: 3588517
[TBL] [Abstract][Full Text] [Related]
17. Aripiprazole for treatment-resistant schizophrenia: results of a multicenter, randomized, double-blind, comparison study versus perphenazine.
Kane JM; Meltzer HY; Carson WH; McQuade RD; Marcus RN; Sanchez R;
J Clin Psychiatry; 2007 Feb; 68(2):213-23. PubMed ID: 17335319
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of the combination of fluoxetine and perphenazine in the treatment of psychotic depression.
Rothschild AJ; Samson JA; Bessette MP; Carter-Campbell JT
J Clin Psychiatry; 1993 Sep; 54(9):338-42. PubMed ID: 8104930
[TBL] [Abstract][Full Text] [Related]
19. [Perphenazine. Indications].
Van Steenkiste J
Psychopharmacologie; 1971; ():63-70. PubMed ID: 5162008
[No Abstract] [Full Text] [Related]
20. Perphenazine-benztropine mesylate treatment of newly admitted psychiatric patients.
Hanlon TE; Schoenrich C; Freinek W; Turek I; Kurland AA
Psychopharmacologia; 1966; 9(4):328-39. PubMed ID: 4874349
[No Abstract] [Full Text] [Related]
[Next] [New Search]
